A simple and rapid high-performance liquid chromatographic method has been developed for the determination of vigabatrin concentrations in plasma or serum. The assay uses only 100 mL of specimen and has been found to be linear over a concentration range of 1 to 50 mg/L. The limit of detection has been determined as 1 mg/L, and the between-batch coef®cient of variation for the two internal quality controls routinely analysed (n=33) has been found to be less than 5%. There was no evidence of interferences in the assay from other commonly prescribed anti-epileptic drugs.
INTRODUCTION
Vigabatrin (g-vinyl-aminobutyric acid) is one of the newer generation of anti-epileptic drugs introduced into the UK in 1989. Vigabatrin was speci®cally designed to inhibit the enzyme g-aminobutyrate-a-ketoglutarate aminotransferase (GABA-transaminase). The drug binds covalently to the active site of the enzyme, consuming both enzyme and inhibitor in an irreversible reaction. 1 In this way, vigabatrin increases the concentrations of the inhibitory neurotransmitter g-aminobutyric acid (GABA) in the brain in a dose-dependent manner, thereby increasing seizure control in resistant epilepsy. 2, 3 Vigabatrin is supplied as a racemic mixture but only the S(+) isomer is active. The drug is rapidly absorbed, with maximal concentrations occurring within 1 to 2 h, and an elimination half-life of around 7 to 8 h in young adults. 4 In elderly patients, the time to maximal concentration, elimination half-life and area under the curve are signi®cantly greater than those in young adults. 1, 4 This could be linked to the renal clearance of the drug, which is the primary route of elimination and appears to be enantiomerselective, with the S(+) isomer being eliminated more rapidly in patients with renal disorders. 1, 3, 4 The drug is not metabolized or is only weakly metabolized 4 and is not protein-bound. 1 Vigabatrin appears to be well tolerated, with the most commonly reported adverse reactions being drowsiness (12% incidence), fatigue (9%), dizziness (4%) and headache (4%). In addition, behavioural changes and agitation have been noted in approximately 5% of epileptic patients undergoinglong-term treatmentwith vigabatrin. 1 The potential for drug interactions between anti-epileptic drugs should always be considered, since they are often prescribed for concomitant use. This is especially true for the newer generation of anti-epileptic drugs, which are used as adjunct treatments in refractory epilepsy. It has been found that vigabatrin may give rise to reduced phenobarbitone concentrations, but it will lead to a 20% to 30% reduction in phenytoin concentrations when these are taken together, which may result in therapeutic failure. 1, 5 The mechanism for this effect is still to be elucidated but is not linked to changes in hepatic metabolism or protein-binding of phenytoin 1 or its bioavailability. 5 There have been several methods published for the analysis of vigabatrin. These range from gas chromatography with mass spectrometry 6 to high-performance liquid chromatographic (HPLC) techniques. 7, 8 All of these methods were primarily developed to determine the pharmacokinetics of the isomers of vigabatrin rather than for routine clinical monitoring. It was for this reason that a rapid (less than 5-min run time) and simple method was developed to allow the routine determination of vigabatrin in epileptic patients as an aid to their treatment.
Although apparently well tolerated, it can be seen that there are several areas in which therapeutic monitoring could aid in the optimization of treatment with vigabatrin. These areas are: following alterations in concomitant medication; adverse reactions; in epileptic patients with reduced renal function; and to investigate therapeutic failures, which may be related to patient compliance. In addition, a proposed target range of 5 to 35 mg/L has been suggested for vigabatrin.
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METHODS
Materials and equipment
The vigabatrin used was a gift from Merrell Dow Research Institute, Cincinnati, USA. Acetonitrile and methanol were both HPLC grade (Rathburn, Walkerburn, UK). Borax, picrylsulphonic acid and tranexamic acid were all from Sigma-Aldrich Co Ltd, (Poole, UK). Ammonium acetate and orthophosphoric acid were both AnalaR grade (BDH, Lutterworth, UK), and glacial acetic acid was AR grade (May and Baker, Dagenham, UK).
The analysis was performed at room temperature using a Kontron MI1660 autosampler ®tted with a 20-mL sample loop (Sci-Tek Instruments, Olney, UK) in conjunction with a Pye Unicam LC-UV detector (Unicam Ltd, Cambridge, UK) with wavelength set at 340 nm, a Gynkotek HPLC model 300 pump (Dionex Ltd, Maccles®eld, UK) and a Hewlett-Packard HP3394 integrator (Hewlett-Packard Ltd, Stockport, UK). The column was 100 mm2 4´6 mm Spherisorb 5 mm ODS2 (Phase Separations Ltd, Deeside, UK) with a 10 mm2 3´2 mm Spherisorb ODS2 guard column (Hichrom Ltd, Reading, UK). The mobile phase comprised 520 mL acetonitrile, 130 mL 40 mmol/L acetate buffer (prepared from ammonium acetate and acetic acid to pH 3´5), 350 mL water and 100 mL of 10 mmol/L orthophosphoric acid (added as a modi®er to improve the chromatography). Thē ow rate was maintained at 1´0 mL/min.
Standards and quality controls
Vigabatrin standards at concentrations of 5, 10, 25 and 50 mg/L and internal quality controls at concentrations of 20 and 40 mg/L were prepared in plasma and stored frozen at 3 20 Ê C in 1 mL aliquots until required. There was no relevant external quality assurance scheme available at the time of study.
Patient selection
Specimens were submitted for analysis from 12 sources throughout the West Midlands, UK, over a 12-month period, for either therapeutic monitoring or because of therapeutic failure in seizure control. The patient demographics are given in Table 1 .
Specimen analysis
Plasma or serum measurements of vigabatrin were performed as follows. Into a 1´9-mL polypropylene Eppendorf capped tube were placed 100 mL of plasma standard, quality control or specimen, to which was added 400 mL of acetonitrile. The tube was then capped and vortex-mixed for 30 s. Following centrifugation at 13 000 rpm for 5 min, the upper layer was decanted into a 12-mL polypropylene tube. This extract was then evaporated to dryness at 45 Ê C under air. One hundred microlitres of external standard (tranexamic acid, 10 mg/L in saturated borax solution) and 3 mL of the derivatizing agent (picrylsulphonic acid) were then added to the 12 mL polypropylene tube which was vortexmixed brie¯y and incubated in a 50 Ê C water bath for 10 min. Following incubation, 200 mL of 0´25 mol/L acetic acid was added to each tube and vortex-mixed brie¯y. Finally, the extract was diluted 1:1 with mobile phase prior to injection using the 20-mL loop on the autosampler. Under the above conditions, the retention times were found to be 2´3 min for vigabatrin and 2´9 min for the external standard tranexamic acid (see Fig. 1 ). Standard calibration curves for vigabatrin were performed using concentrations of 5, 10, 25 and 50 mg/L. A calibration curve was run for each batch of specimens analysed, and the derived concentration of vigabatrin was calculated by the integrator from a regression analysis performed on the standard calibration curve.
RESULTS
The tranexamic acid was used as an external standard due to its instability when taken through the extraction process. The absolute recovery (comparing neat drug solutions to plasma extracts) over the range of 5 to 50 mg/L was found to vary between 62% and 84%, with a mean recovery of 73% when using vigabatrin chromatographic peak height.
It was found that the assay described above was linear over the calibration range of 1 to 50 mg/L. Any specimens found to contain vigabatrin concentrations above 50 mg/L were diluted with blank plasma and re-analysed. The limit of detectionfor the assay was set at 1´0 mg/L. The reproducibility of the assay was determined by assaying the 50 mg/L standard 10 times, which gave a percentage coef®cient of variation (%CV) of 2´7%. The between-batch variation was determined from 33 separate analyses of the two internal quality controls. The mean concentration determined for the 20 mg/L quality control was found to be 19´8 mg/L with a %CV of 4´4%. The 40 mg/L quality control gave a mean value of 39´5 mg/L with a %CV of 3´3%. No interferences from high concentrations of other routinely prescribed anti-epileptic drugs (namely, carbamazepine at 17´4 mg/L, ethosuximide at 162 mg/L, gabapentin at 40 mg/L, lamotrigine at 30 mg/L, phenobarbitone at 61 mg/L, phenytoin at 28 mg/L and valproic acid at 150 mg/L) have been observed since the assay has been in routine operation.
The results of the application of this method to the analysis of patient specimens are illustrated in Fig. 2 . It can be seen that for the male group, 26% of results were below and 11% were above the proposed target range of 5±35 mg/L. For the female group, 36% were below and 11% were above the target range. This data indicates that only 63% of male and 53% of female patients monitored had concentrations within the proposed target range. The maximum measured plasma concentration determined in the male group was 52´8 mg/L and that in the female group was 61´4 mg/L.
It can be seen from the breakdown of the patient demographics in Table 1 that there is a bias toward the use of vigabatrin in the younger population, with the median age being lower than the mean age in both male and female patient groups.
No relationship was found between the concentration of vigabatrin determined and the dose of vigabatrin prescribed (r 2 =0´0098). In addition, there was no relationship between the vigabatrin concentration and the age of the patients (r 2 =0´0022), although the dose data are sparse since the initial request forms accompanying the specimens contain very limited information. It also should be remembered that the compliance of patients admitted to hospitals with seizures must also be questioned. 
DISCUSSION
A simple and rapid HPLC method to determine the concentration of vigabatrin in plasma or serum of patients treated with the drug for seizure control has been developed and validated. The assay has been found to be both sensitive and reproducible, and uses only 100 mL of specimen. The assay has now been in routine operation within the authors' laboratory for approximately 1 year and no interferences have been observed with the method to date.
The wide range of vigabatrin concentrations determined re¯ects, in part, the issues associated with therapeutic drug monitoring. When drugs are prescribed according to clinical end-points then individualization of treatments is achievable. However, when patients in the community are prescribed prophylactic treatments that are seldom monitored (unless patients are admitted to hospital), then individualization of drug treatments is unlikely to occur. The maximum concentration in the male group was found to be 52´8 mg/L and in the female group 61´4 mg/L. Both of these values approximate to double the top of the proposed target range.
There are also the problems associated with non-compliance of patients in the community, 10 and polypharmacy leading to drug interactions which could impact on the ef®cacy of the combined drug treatments. 1, 5, 11 It was found that 16% of male patients and 21% of female patients studied had concentrations of vigabatrin below the limit of detection of the assay, indicating that they were non-compliant. It can therefore be seen that dose optimization may be better achieved through routine monitoring of patients prescribed vigabatrin. Since it was beyond the scope of this study to determine any correlation between ®t frequency and the measured concentrations of vigabatrin, the clinical effects of these low drug concentrations were not elucidated.
The lack of a relationship between vigabatrin dose and concentration is not surprising since no two subjects will handle a drug in the same manner, which is the whole basis of the application of therapeutic monitoring to optimize drug treatments. It is known that vigabatrin produces a dose-dependent increase in brain GABA concentration 2, 3 but the effects of this increase, and therefore the ef®cacy of the treatment, will again be subjective. This means that`standardized' doses will not apply to every case of epilepsy treated with vigabatrin, again providing a reason for routine monitoring of treatments commenced in hospital but continued in the community.
Although this article only gives an overview of the concentrations of vigabatrin found in patients suffering from epilepsy, it is hoped that it will encourage increased therapeutic monitoring of patients in the community, and provide explanations for therapeutic failure or overdose.
